EFG International AG Takes $4.57 Million Position in Bristol Myers Squibb Company $BMY

EFG International AG purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 79,256 shares of the biopharmaceutical company’s stock, valued at approximately $4,566,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. Norges Bank bought a new stake in shares of Bristol Myers Squibb during the fourth quarter worth approximately $1,947,272,000. Primecap Management Co. CA acquired a new position in Bristol Myers Squibb in the second quarter valued at approximately $1,436,115,000. Legal & General Group Plc bought a new position in Bristol Myers Squibb in the second quarter valued at approximately $980,862,000. AQR Capital Management LLC grew its holdings in Bristol Myers Squibb by 172.6% during the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after acquiring an additional 16,332,924 shares during the period. Finally, BlackRock Inc. grew its holdings in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares during the period. 76.41% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on BMY shares. Roth Capital began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target on the stock. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. TD Cowen assumed coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating on the stock. Sanford C. Bernstein upgraded Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Finally, Piper Sandler began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an “overweight” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Stock Up 0.9%

Shares of BMY stock opened at $67.86 on Wednesday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The firm has a fifty day moving average of $61.01 and a 200-day moving average of $59.54. The company has a market capitalization of $138.62 billion, a price-to-earnings ratio of 14.95, a P/E/G ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities research analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.7%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.